Skip to main content

Table 1 Characteristics of included studies

From: Intravenous versus intravenous/oral antibiotics for perforated appendicitis in pediatric patients: a systematic review and meta-analysis

Study

Study type

Sample size

Age (years, mean ± SD)

Type of antibiotic

Length of antibiotic therapy (days, mean ± SD)

NOS/JS

Henry E. Rice 2001

RCT

IV/PO: 16

11.9 ± 3.9

IV: Ampicillin & gentamicin sulfate & clindamycin/PO: amoxicillin-clavulanate

10.1 ± 0.5

3

IV: 10

12.5 ± 3.7

IV:Ampicillin & gentamicin sulfate & clindamycin

10.4 ± 1.3

Obinna O. Adibe 2008

OCS

IV/PO: 47

9.7 ± 0.52

IV: Ampicillin–Sulbactam & Gentamicin OR Ampicillin–Sulbactam/PO: TMP-SMX & Metronidazole

14 ± 0

8

IV:102

8.8 ± 0.41

IV:Ampicillin–Sulbactam & Gentamicin OR Ampicillin–Sulbactam

14 ± 0

Jason D. Fraser 2010

RCT

IV/PO: 50

10.1 ± 4.6

IV: Ceftriaxone & Metronidazole/PO: Amoxicillin-Clavulanate

≥ 5

2

IV: 52

9.7 ± 4.2

IV:Ceftriaxone & Metronidazole

7 ± 0

Shannon N. Acker 2016

OCS

IV/PO: 291

9.7 ± 4.1

IV: Ceftriaxone & Metronidazole/PO: NA

NA

8

IV: 34

8.9 ± 4.5

IV:Ceftriaxone & Metronidazole followed by other types for home antibiotic

NA

Tara J. Loux 2016

OCS

IV/PO: 123

10.24 ± 4.3

IV: Piperacillin-Tazobactam/PO: TMP-SMX & Metronidazole

15.2 ± 8.4

7

IV: 98

10.51 ± 4.4

IV:Piperacillin-Tazobactam followed by other types for home antibiotic

15.2 ± 8.5

Michael R. Arnold 2018

RCT

IV/PO: 38

10.1 ± 3.6

IV: Ertapenem/PO: Amoxicillin-clavulanate

10 ± 0

3

IV: 44

12.3 ± 3.6

IV:Ertapenem

10 ± 0

  1. RCT: Randomized controlled trial; OCS: Observational clinical study; IV: Intravenous; PO: Oral; NA: Not available; NOS: Newcastle-Ottawa Scale score; JS: Jadad score